

# Ryzneuta® (efbemalenograstim alfa-vuxw) (Subcutaneous)

Document Number: IC-0741

Last Review Date: 01/04/2024

Date of Origin: 01/04/2024

Dates Reviewed: 01/2024

## I. Length of Authorization

Coverage will be provided for four months and may be renewed unless otherwise specified.

## II. Dosing Limits

### A. Quantity Limit (max daily dose) [NDC Unit]:

- Ryzneuta 20 mg/mL prefilled syringe: 1 syringe per 14 days

### B. Max Units (per dose and over time) [HCPCS Unit]:

- 20 mg per 14 days

## III. Initial Approval Criteria <sup>1</sup>

Coverage is provided in the following conditions:

Nyvepria and Fulphila are the preferred long-acting granulocyte colony-stimulating factor products.

- Patients must have failed, or have a contraindication, or intolerance to Nyvepria AND Fulphila prior to consideration of any other long-acting G-CSF product; **AND**
- Patient is at least 18 years of age; **AND**
- Will not be used for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation; **AND**
- Patient does not have a history of serious allergic reactions to granulocyte stimulating factor products (e.g., pegfilgrastim, filgrastim, etc.); **AND**

### Prophylactic use in patients with non-myeloid malignancy † ‡ <sup>1-7,9,10,12,13,15,17,27-29</sup>

- Patient is undergoing myelosuppressive chemotherapy with an expected incidence of febrile neutropenia of greater than 20% §; **OR**
- Patient is undergoing myelosuppressive chemotherapy with an expected incidence of febrile neutropenia of 10% to 20% § **AND** one or more of the following co-morbidities:
  - Age >65 years receiving full dose intensity chemotherapy
  - Extensive prior exposure to chemotherapy

- Previous exposure of pelvis, or other areas of large amounts of bone marrow, to radiation
- Pre-existing neutropenia (ANC  $\leq$  1000/mm<sup>3</sup>)
- Bone marrow involvement with tumor
- Patient has a condition that can potentially increase the risk of serious infection (i.e., HIV/AIDS with low CD4 counts)
- Recent surgery and/or open wounds
- Poor performance status
- Renal dysfunction (creatinine clearance  $<$ 50 mL/min)
- Liver dysfunction (elevated bilirubin  $>$ 2.0 mg/dL)
- Chronic immunosuppression in the post-transplant setting including organ transplant

Note: Dose-dense therapy, in general, requires growth factor support to maintain dose intensity and schedule. In the palliative setting, consideration should be given to dose reduction or change in regimen.

§Febrile neutropenia is defined as: <sup>7</sup>
– <u>Temperature</u> : a single temperature $\geq$ 38.3 °C orally or $\geq$ 38.0 °C over 1 hour; <b>AND</b>
– <u>Neutropenia</u> : $<$ 500 neutrophils/mcL or $<$ 1,000 neutrophils/mcL and a predicted decline to $\leq$ 500 neutrophils/mcL over the next 48 hours
§ Expected incidence of febrile neutropenia percentages for myelosuppressive chemotherapy regimens can be found in the NCCN Hematopoietic Growth Factors Clinical Practice Guideline at NCCN.org <sup>7</sup>

† FDA-Approved Indication(s); ‡ Compendium Recommended Indication(s); Ⓢ Orphan Drug

#### IV. Renewal Criteria <sup>1</sup>

Coverage may be renewed based on the following criteria:

- Patient continues to meet indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: splenic enlargement/rupture, acute respiratory distress syndrome, severe hypersensitivity reactions/anaphylaxis, severe sickle cell crises in patients with sickle cell disease, glomerulonephritis, hematologic effects (e.g., leukocytosis, thrombocytopenia), capillary leak syndrome, tumor cell mobilization, MDS/AML in patients with breast and lung cancer, aortitis, etc.

#### V. Dosage/Administration <sup>1</sup>

Indication	Dose

Prophylactic use in patients with non-myeloid malignancy	– Administer 20 mg subcutaneously once per chemotherapy cycle at least 24 hours after cytotoxic chemotherapy. Do not administer within 14 days before and <24 hours after administration of cytotoxic chemotherapy.
<i>Note: Ryzneuta is administered subcutaneously via a single-dose prefilled syringe by a healthcare professional.</i>	

## VI. Billing Code/Availability Information

### HCPCS Code:

- J3590 – Unclassified biologics

### NDC:

- Ryzneuta 20 mg/mL prefilled syringe: 73491 -0627-xx

## VII. References

1. Ryzneuta [package insert]. Singapore; Evive Biotech., LTD; November 2023. Accessed December 2023.
2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) efbemalenograstim. National Comprehensive Cancer Network, 2023. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed December 2023.
3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hematopoietic Cell Transplantation Version 3.2023. National Comprehensive Cancer Network, 2023. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed December 2023.
4. Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015 Oct 1;33(28):3199-212. doi: 10.1200/JCO.2015.62.3488.

## Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
D61.81	Pancytopenia
D70.1	Agranulocytosis secondary to cancer chemotherapy
D70.9	Neutropenia, unspecified

ICD-10	ICD-10 Description
T45.1X5A	Adverse effect of antineoplastic and immunosuppressive drugs initial encounter
T45.1X5D	Adverse effect of antineoplastic and immunosuppressive drugs subsequent encounter
T45.1X5S	Adverse effect of antineoplastic and immunosuppressive drugs sequela
Z41.8	Encounter for other procedures for purposes other than remedying health state
Z51.11	Encounter for antineoplastic chemotherapy
Z51.12	Encounter for antineoplastic immunotherapy
Z51.89	Encounter for other specified aftercare
Z76.89	Persons encountering health services in other specified circumstances

## Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determinations (NCDs) and/or Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications, including any preceding information, may be applied at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCA/LCD): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC